TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3354541

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 379
Study: 31409509

Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER) - 48 hours of 600 kcal/day followed by 5 days of healthy eating advice
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER) - 500 kcal/day healthy eating advice
Number of subjects: 43
Study: 31430267

Group type: EXPERIMENTAL
Intervention: Case-crossover analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-controlled case series
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both designs
Number of subjects: 0
Study: 28471931

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-Team-Based Learning (non-TBL)
Number of subjects: 87
Study: 26902043

Group type: COMPARATOR
Intervention: Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acute Normovolemic Hemodilution (ANH) + Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study: 23744953

Group type: EXPERIMENTAL
Intervention: Subcostal TAP block (group TAP) with 20 mL of 0.375% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (group EA) with 8 mL of 0.25% ropivacaine before induction and maintained with 5 mL/h of 0.25% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV opioid analgesia (group GA)
Number of subjects: 90
Study: 20927038

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 19133220

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16675759

Group type: EXPERIMENTAL
Intervention: Algorithm-based care for major depression
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Algorithm-based care for bipolar disorder
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Algorithm-based care for schizophrenia
Number of subjects: 926

Group type: COMPARATOR
Intervention: Usual care for major depression
Number of subjects: 926

Group type: COMPARATOR
Intervention: Usual care for bipolar disorder
Number of subjects: 926

Group type: COMPARATOR
Intervention: Usual care for schizophrenia
Number of subjects: 926
Study: 14559046

Group type: EXPERIMENTAL
Intervention: Stabilizing training (ST group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Manual treatment (MT group)
Number of subjects: 47
Study: 10762020

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Fenretinide (4-HPR)
Number of subjects: 0
Study: 8955967

Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.025 mg.kg‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.050 mg.kg‐1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous morphine 0.050-0.150 mg.kg‐1
Number of subjects: 18
Study: 1316584

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2990890

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 45

Group type: COMPARATOR
Intervention: No contact (Control)
Number of subjects: 45
Study: 31433542

Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro (FLP) continuous glucose monitor
Number of subjects: 33
Study: 29474479

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding promotion by peer counsellors
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no exclusive breastfeeding promotion)
Number of subjects: 1000
Study: 27823869

Group type: EXPERIMENTAL
Intervention: Mavoglurant 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mavoglurant 50 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (oral)
Number of subjects: 36
Study: 24666438

Group type: EXPERIMENTAL
Intervention: Intervention group: standardized training for PHCT professionals, 1 individualized counselling session, 1 family session, and 4 educational group sessions, along with usual home health care visits, periodic telephone follow-up, and unlimited telephone support.
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group: usual home health care consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request.
Number of subjects: 282
Study: 22963754

Group type: COMPARATOR
Intervention: 2% lidocaine gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% tetracaine gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1% tetracaine solution
Number of subjects: 10
Study: 21064010

Group type: EXPERIMENTAL
Intervention: Procaine infusion (1% solution, 8 ml/h, 1.92 g/24 h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo infusion (0.9% saline solution)
Number of subjects: 42
Study: 18380127

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14745070

Group type: EXPERIMENTAL
Intervention: Valproic acid (1,500 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 31
Study: 12193977

Group type: EXPERIMENTAL
Intervention: 7.5 mg warfarin daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg warfarin daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg warfarin daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 mg phenprocoumon daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 mg phenprocoumon daily
Number of subjects: 0
Study: 9951899

Group type: EXPERIMENTAL
Intervention: Anterior mediastinal approach
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Posterior mediastinal approach
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (anterior and posterior)
Number of subjects: 38
Study: 7806021

Group type: EXPERIMENTAL
Intervention: Steady‐state focal electroretinogram at the macula
Number of subjects: 0
Study: 2594898

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 40 or 80 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 1.0 or 2.0 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28474866

Group type: EXPERIMENTAL
Intervention: Gymnastics training (G)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 12
Study: 27680484

Group type: EXPERIMENTAL
Intervention: Fentanyl 30 μg/mL
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fentanyl 15 μg/mL
Number of subjects: 47
Study: 25335375

Group type: EXPERIMENTAL
Intervention: Lingual bar design
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lingual plate design
Number of subjects: 15
Study: 23523674

Group type: EXPERIMENTAL
Intervention: Immediate pegylated interferon alfa-2b treatment for 24 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Delayed pegylated interferon alfa-2b plus ribavirin treatment starting 12 weeks after randomisation if HCV RNA remained positive
Number of subjects: 132

Group type: COMPARATOR
Intervention: Delayed pegylated interferon alfa-2b plus ribavirin treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Immediate treatment (symptomatic or asymptomatic)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients receiving immediate treatment
Number of subjects: 132
Study: 21355441

Group type: EXPERIMENTAL
Intervention: procaterol
Number of subjects: 14
Study: 18296986

Group type: EXPERIMENTAL
Intervention: External nasal dilator (END)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Without external nasal dilator (without END)
Number of subjects: 23
Study: 16571393

Group type: EXPERIMENTAL
Intervention: Facilitation technique (FT) coupled with body weight‐supported treadmill training (BWSTT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Mechanical assistance (control) during BWSTT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Facilitation technique (FT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Mechanical assistance (control)
Number of subjects: 49
Study: 14701891

Group type: EXPERIMENTAL
Intervention: SAVIT study intervention (details not specified)
Number of subjects: 10
Study: 12580236

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 12
Study: 9538651

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No streptokinase treatment (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stable ischaemic heart disease (Control Group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy subjects (Control Group 4)
Number of subjects: 80
Study: 1493087

Group type: EXPERIMENTAL
Intervention: Trimethoprim (150 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole (160 and 800 mg)
Number of subjects: 9
Study: 3895099

Group type: EXPERIMENTAL
Intervention: Intensive cyclic therapy (using drugs like AMSA, 5-AZA, and HD-araC) during remission induction.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Immediate intensive remission induction.
Number of subjects: 266

Group type: COMPARATOR
Intervention: Supportive care, 'wait and see' policy, and palliative cytoreduction with hydroxyurea and ara C when necessary.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Maintenance arm I (specific drugs not detailed).
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Maintenance arm II (specific drugs not detailed).
Number of subjects: 266
Study: 31012052

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the acute phase of care
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the plateau phase of care
Number of subjects: 218
Study: 29267940

Group type: EXPERIMENTAL
Intervention: Metacognition-Oriented Social Skills Training (MOSST)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional Social Skills Training (SST)
Number of subjects: 69
Study: 27629292

Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Conventional oral antipsychotics (COAs)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Atypical oral antipsychotics (AOAs)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Oral paliperidone/risperidone
Number of subjects: 444
Study: 23782685

Group type: EXPERIMENTAL
Intervention: Simulation training (box trainer or virtual reality simulator)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 138
Study: 22240495

Group type: EXPERIMENTAL
Intervention: MVD with CTO in a non-IRA
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: MVD without CTO
Number of subjects: 3283

Group type: COMPARATOR
Intervention: SVD
Number of subjects: 3283
Study: 20307730

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31
Study: 18796619

Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol (task delegation to a practice nurse, computerized decision support, feedback every 3 months)
Number of subjects: 3391

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 3391

Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol
Number of subjects: 3391
Study: 16552830

Group type: EXPERIMENTAL
Intervention: wen-jing-tang (unkei-to)
Number of subjects: 64

Group type: COMPARATOR
Intervention: continuation of preceding Kampo prescription
Number of subjects: 64
Study: 14700374

Group type: EXPERIMENTAL
Intervention: Experimental group (N = 20) heard the label of each verb 13 times while viewing the story
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (N = 20) did not hear the verbs' labels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental subgroup (N = 6) who correctly identified more than half of the target verbs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adult group (N = 22) who did not view the story
Number of subjects: 40
Study: 10821985

Group type: EXPERIMENTAL
Intervention: Oral cotinine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9374603

Group type: EXPERIMENTAL
Intervention: Color photographs of the murder victim
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Black and white photographs of the murder victim
Number of subjects: 120

Group type: COMPARATOR
Intervention: No photographs (control condition)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All conditions (color, black and white, no photographs)
Number of subjects: 120
Study: 1311794

Group type: EXPERIMENTAL
Intervention: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day) + Vaginal progesterone (P4; 100 mg twice daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study: 4021803

Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study: 31818055

Group type: EXPERIMENTAL
Intervention: Visual Training (VT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Training (Control Group)
Number of subjects: 20
Study: 31172667

Group type: EXPERIMENTAL
Intervention: FBCx + GINST15
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FBCx + placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: placebo + GINST15
Number of subjects: 400

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 400
Study: 28482621

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy and kinesitherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Kinesitherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 69
Study: 25421475

Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg and 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-451840
Number of subjects: 0
Study: 22526973

Group type: EXPERIMENTAL
Intervention: Laser dissection (L)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard stapler technique (S)
Number of subjects: 44
Study: 21221004

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: HUI mark III
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Both measures
Number of subjects: 429
Study: 19500809

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise (1-2 hours at 60% of peak oxygen consumption)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 27
Study: 16837887

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg daily and 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Transdermal estradiol (TE2) 50 mcg twice weekly and 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE)
Number of subjects: 92
Study: 14992985

Group type: EXPERIMENTAL
Intervention: Pramipexole (mean maximum dose=1.7 mg/day, SD=1.3)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 22
Study: 11376503

Group type: EXPERIMENTAL
Intervention: Microstream capnometer (NBP‐75, Nellcor Puritan Bennett) with an aspiration flow rate of 30 ml.min‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional sidestream capnometer with a 200 ml.min‐1 aspiration flow rate
Number of subjects: 30
Study: 9262843

Group type: EXPERIMENTAL
Intervention: High-flux dialysis with ultrapure bicarbonate hemodialysis (HD)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Predilution hemofiltration (HF)
Number of subjects: 23
Study: 8111816

Group type: EXPERIMENTAL
Intervention: 30 mg/day nifedipine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 60 mg/day nifedipine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 90 mg/day nifedipine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 245
Study: 3713162

Group type: EXPERIMENTAL
Intervention: Knee angle between 175-180°
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Knee angle between 155-160°
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Knee angle between 134-140°
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 16
Study: 30509244

Group type: EXPERIMENTAL
Intervention: Single row technique using two knotted 3.0 mm suture anchors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double row technique using an additional knotless 3.5 mm anchor
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single row technique
Number of subjects: 12
Study: 27116931

Group type: EXPERIMENTAL
Intervention: Web-based eLearning training programme
Number of subjects: 130
Study: 24475840

Group type: EXPERIMENTAL
Intervention: CE T1-weighted subtraction maps
Number of subjects: 160
Study: 22488107

Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS), single oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS), daily oral doses for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin, lower doses than used for anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS)
Number of subjects: 0
Study: 20829712

Group type: EXPERIMENTAL
Intervention: ACEi (enalapril 20 mg/day) during high salt (200 mmol Na/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ACEi (enalapril 20 mg/day) during low salt (50 mmol Na/day)
Number of subjects: 35
Study: 16988909

Group type: EXPERIMENTAL
Intervention: 20 g protein (14 g whey and casein protein, 6 g free amino acids)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 20 g dextrose placebo
Number of subjects: 19
Study: 16195987

Group type: EXPERIMENTAL
Intervention: Hypoxia (inspired O2 fraction = 16 %)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 9
Study: 11900103

Group type: EXPERIMENTAL
Intervention: Comparison of 2 perceptually similar category members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing common labels for targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing conflicting labels for targets
Number of subjects: 0
Study: 10435264

Group type: EXPERIMENTAL
Intervention: Alcohol self-administration study with naltrexone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 21
Study: 7477988

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) 50 micrograms
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2115348

Group type: EXPERIMENTAL
Intervention: Dietary instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple follow up without instruction (Control)
Number of subjects: 0
Study: 7381649

Group type: EXPERIMENTAL
Intervention: 43 microgram HA vaccine
Number of subjects: 31

Group type: COMPARATOR
Intervention: 10 microgram HA vaccine
Number of subjects: 31

Group type: COMPARATOR
Intervention: 4 microgram HA vaccine
Number of subjects: 31
Study: 31699651

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall anesthesia types
Number of subjects: 93
Study: 29508470

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 8120

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 8120

Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Number of subjects: 8120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8120
Study: 25724391

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 115
Study: 23778240

Group type: EXPERIMENTAL
Intervention: Comprehensive couples‐based PMTCT intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 239
Study: 22027579

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg, increased to 30 or 60 mg if needed)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 120
Study: 18722585

Group type: EXPERIMENTAL
Intervention: Spaced education residents
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control residents
Number of subjects: 324
Study: 17944013

Group type: EXPERIMENTAL
Intervention: High doses of epinephrine (5 mg each)
Number of subjects: 2910

Group type: COMPARATOR
Intervention: Standard doses of epinephrine (1 mg each)
Number of subjects: 2910

Group type: EXPERIMENTAL
Intervention: Trauma patients discharged
Number of subjects: 2910

Group type: COMPARATOR
Intervention: Medical patients discharged
Number of subjects: 2910
Study: 15172463

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intracoronary beta-radiation therapy (ICR)
Number of subjects: 22
Study: 12134110

Group type: EXPERIMENTAL
Intervention: Fiber-containing formula plus living Lactobacillus plantarum 299
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fiber-containing formula plus heat-killed Lactobacillus plantarum 299
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard formula plus selective bowel decontamination (SBD)
Number of subjects: 95